ZFP36L1 and acute myeloid leukemia: Similar to our findings in SCLC (see Fig. 4), CRISPR-mediated ZFP36L1 inactivation caused near complete resistance to ORY-1001 in 2 of the 3 AML cell lines (Fig. 7h, i) with the exception being HEL cells, which showed a weaker induction of ZFP36L1 protein expression upon ORY-1001 treatment (Fig. 7g).